Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Assessment of EBV DNA methlyation to guide antiviral use in EBV-associated lymphoma

Cara Noel, Christoph Weigel, Haley Klimaszewski, Kurtis Host, Yue-Zhong Wu, Sarah Schlotter, Elshafa Ahmed, Eric Brooks, James Blachly, Mark Lustberg, Timothy Voorhees, Christopher Oakes, Robert Baiocchi

Blood (2025) 146 (Supplement 1): 1752.

https://doi.org/10.1182/blood-2025-1752

Published: 2025

Journal Articles

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Blood (2025) 146 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2025-2385

Published: 2025

Journal Articles

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Blood (2025) 146 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2025-1841

Published: 2025

Journal Articles

Evaluation of outcomes by line of therapy in marginal zone lymphoma: Real-world evidence from 10 US academic centers

Narendranath Epperla, John Sharp, Natalie Grover, Marcus Watkins, Reem Karmali, Pallawi Torka, Timothy Voorhees, Colin Thomas, Stefan Barta, Praveen Ramakrishnan Geethakumari, Nancy Bartlett, Geoffrey Shouse, Adam Olszewski

Blood (2025) 146 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2025-4533

Published: 2025

Journal Articles

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Alyssa Kassouf, Rina Welkie, Yazeed Sawalha, Audrey Sigmund, Timothy Voorhees, Yun Choi, Robert Baiocchi, Jordan Lundberg, Tracy Wiczer, Tyler Everhardt, Caitlyn Crawford, Rebecca Evers, Lindsay Rosen, Beth Christian, Kami Maddocks, David Bond

Blood (2025) 146 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2025-4526

Published: 2025

Journal Articles

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Blood (2025) 146 (Supplement 1): 3671.

https://doi.org/10.1182/blood-2025-3671

Published: 2025

Journal Articles

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Blood (2025) 146 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2025-1798

Published: 2025

Journal Articles

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Blood (2025) 146 (Supplement 1): 1935.

https://doi.org/10.1182/blood-2025-1935

Published: 2025

Journal Articles

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Blood (2025) 146 (Supplement 1): 265.

https://doi.org/10.1182/blood-2025-265

Published: 2025

Journal Articles

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Timothy Voorhees, Rina Welkie, Hemalatha Rao, Yazeed Sawalha, David Bond, Audrey Sigmund, Yun Choi, John Reneau, Walter Hanel, Polina Shindiapina, Jonathan Brammer, Beth Christian, Lapo Alinari, Nancy Bartlett, Kami Maddocks, Robert Baiocchi

Blood (2025) 146 (Supplement 1): 8240.

https://doi.org/10.1182/blood-2025-8240

Published: 2025

Journal Articles

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Yazeed Sawalha, Marie Hu, Rina Welkie, Aubree Shoemaker, Yun Choi, Audrey Sigmund, Timothy Voorhees, David Bond, John Reneau, Lapo Alinari, Jonathan Brammer, Beth Christian, Robert Baiocchi, Veronika Bachanova, Kami Maddocks

Blood (2025) 146 (Supplement 1): 8239.

https://doi.org/10.1182/blood-2025-8239

Published: 2025

Journal Articles

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Blood (2025) 146 (Supplement 1): 3622.

https://doi.org/10.1182/blood-2025-3622

Published: 2025

Journal Articles

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Nikita Dave, Imran Nizamuddin, Neha Mehta-Shah, Edd Ricker, Jennifer Amengual, Robert Baiocchi, Timothy Voorhees, Stefan Barta, Jordan Carter, Elise Chong, Michael Cook, Daniel Landsburg, Stephen Schuster, Colin Thomas, Emily Tomasulo, Jakub Svoboda, Sunita Dwivedy Nasta

Blood (2025) 146 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2025-1963

Published: 2025

Journal Articles

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

Blood (2024) 144 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2024-203753

Published: 2024

Journal Articles

Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Sonia Godbole, Rina Li Welkie, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C. Reneau, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks, Yazeed Sawalha

Blood (2024) 144 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2024-207738

Published: 2024

Journal Articles

A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Blood (2024) 144 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2024-202639

Published: 2024

Journal Articles

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Blood (2024) 144 (Supplement 1): 573.

https://doi.org/10.1182/blood-2024-198008

Published: 2024

Journal Articles

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2024-203798

Published: 2024

Journal Articles

Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM)

John Sharp, Subodh Bhatta, Noah Takacs, Kathleen Tong, Youssef Youssef, David A. Bond, Yazeed Sawalha, Audrey M. Sigmund, Lalit Sehgal, Lapo Alinari, Robert Baiocchi, Kami J. Maddocks, Beth Christian, Timothy Voorhees, Narendranath Epperla

Blood (2024) 144 (Supplement 1): 3737.

https://doi.org/10.1182/blood-2024-194399

Published: 2024

Journal Articles

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood (2024) 144 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2024-198872

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Assessment of EBV DNA methlyation to guide antiviral use in EBV-associated lymphoma

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Evaluation of outcomes by line of therapy in marginal zone lymphoma: Real-world evidence from 10 US academic centers

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM)

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only